Appreciate this presentation. Like others I think it might be helpful in the future to have separate webinars for AL and TTR. Have you any information on a new drug for TTR: SOM0226, under development in Spain by a company called SOMBiotech? They claim that it has potential to clear existing amyloid deposits from the heart. The decision tree for TTR treatment options was of particular interest. I am enrolled in the Tafamidis trial, but of the options currently available Doxy/URSO seems most probable to slow progression. What is your opinion? Has any research focused on why WT TTR primarily effects men? It seems that might somehow shed light on the causes of this condition. Thanks to all involved.